



Xadago in Egypt

The EDA named-patient coordination pathway — indicative 2026

NEUROLOGY · PARKINSON DISEASE ADJUNCT

The clinical situation

Xadago (safinamide) is an FDA-approved oral selective reversible MAO-B inhibitor with glutamate-modulating properties, indicated as adjunctive therapy to levodopa/carbidopa in Parkinson disease patients experiencing “off” episodes. Manufactured by Supernus. Standard dosing is 50 mg once daily, titratable to 100 mg after two weeks; ambient-storage oral tablet with drug-interaction vigilance for serotonergic agents.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating neurologist documents PD with motor fluctuations on stable levodopa and confirms eligibility.
- 2 Treating centre confirmed.** An Egyptian tertiary neurology centre in Cairo, Alexandria, or Giza accepts the case.
- 3 EDA named-patient application.** Clinical rationale, patient reference, and product details are filed under EDA personal-import; customs release coordination.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; ambient-temperature shipment.
- 5 Arrival & administration.** Patient begins once-daily dosing with physician-guided titration; motor diary reassessment at 4-8 weeks.

Indicative economics

Reference US cash-pay range: USD 600–750 per 30-day supply. EDA documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete EDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and EDA review. **Logistics.** Ambient-temperature shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Xadago × Egypt first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/xadago-egypt.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team